Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...

Guggenheim 2 nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. – Fireside chat. Stifel 2025 Healthcare Conference, New York ...

Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat ...

BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced ...

CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, ...

On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. Among evaluable Head and ...

Pyxis Oncology (PYXS) announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin, a first-in-concept antibody-drug conjugate targeting extradomain-B of ...

Pyxis Oncology, Inc. announced that its Compensation Committee has granted stock options for a total of 246,238 shares of its common stock to four newly hired employees, under the 2022 Inducement Plan ...